Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Earnings Guidance for the Fiscal 2014
For the nine months, the company reported revenue of $39,424,886 against $32,858,294 a year ago. Income from operations was $9,939,652 against $10,354,234 a year ago. Net income was $8,695,663 against $8,197,811 a year ago. Income before provision for income taxes was $10,521,013 against $9,997,829 a year ago. Diluted earnings per share were $1.08 against basic and diluted earnings per share of $1.08 a year ago. Net cash provided operating activities was $15,244,465 against net cash used in operating activities of $9,092,042 a year ago. Purchases of property, plant and equipment were $8,645 against $9,290 a year ago.
The company reiterated its fiscal 2014 guidance to be in the range of $46 million to $50 million for the full year.